mHSPC: Assessing Patient Response and Selecting 2L Therapy at Progression

Shared insight on strategies to monitor patient response to therapy and select second-line treatment when hormone-sensitive prostate cancer progresses.

Related Videos
Experts on colorectal cancer
Experts on multiple myeloma
Experts on multiple myeloma
Andrew J. Armstrong, MD, MSc, spoke about the recent approval of olaparib plus abiraterone acetate and prednisone in patients with BRCA-mutant metastatic castration-resistant prostate cancer.
Experts on colorectal cancer
Arvind Dasari, MD, MS, an expert on colorectal cancer
Experts on multiple myeloma
Expert on prostate cancer
Experts on multiple myeloma
Related Content